What is Retatrutide?
Retatrutide is an investigational "triple agonist" that activates the GIP, GLP-1 and glucagon receptors simultaneously. It has drawn attention for producing substantial weight reduction in clinical trials and is being studied for obesity and metabolic disease.
Also known as: Reta, LY3437943
Commonly researched for
Research status
Phase III clinical trials — investigational, not yet approved.
Important considerations
Not FDA-approved. Prescription-grade investigational compound; use only under medical supervision.